Am J Cardiovasc Drugs (2018) 18:129–141 https://doi.org/10.1007/s40256-017-0255-y ORIGINAL RESEARCH ARTICLE One-Year Clinical Effectiveness Comparison of Prasugrel with Ticagrelor: Results from a Retrospective Observational Study using an Integrated Claims Database 1,3 2 3 3 • • • • Mark B. Effron Kavita V. Nair Cliff Molife Stuart Y. Keller 2 4 4 4 • • • • Robert L. Page II Jason C. Simeone Brian Murphy Beth L. Nordstrom 3 3 5 • • Yajun Zhu Patrick L. McCollam George W. Vetrovec Published online: 8 December 2017 Springer International Publishing AG, part of Springer Nature 2017 Abstract Methods This retrospective study included patients from a Background No direct comparisons of ticagrelor and pra- payer database who were aged C18 years and had ACS sugrel with 1-year clinical follow-up have been reported. managed with PCI with no history of transient ischemic Objectives Our objective was to compare 1-year clinical attack (TIA)/stroke. Data were propensity matched for outcomes among patients with acute coronary syndrome prasugrel use with a 3:1 prasugrel:ticagrelor ratio. Post- (ACS) managed with percutaneous coronary intervention discharge net adverse clinical event (NACE) rate at 1 year (PCI) and treated with either ticagrelor or prasugrel in a was evaluated for noninferiority
American Journal of Cardiovascular Drugs – Springer Journals
Published: Dec 8, 2017
It’s your single place to instantly
discover and read the research
that matters to you.
Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.
All for just $49/month
Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly
Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.
Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.
Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.
All the latest content is available, no embargo periods.
“Hi guys, I cannot tell you how much I love this resource. Incredible. I really believe you've hit the nail on the head with this site in regards to solving the research-purchase issue.”Daniel C.
“Whoa! It’s like Spotify but for academic articles.”@Phil_Robichaud
“I must say, @deepdyve is a fabulous solution to the independent researcher's problem of #access to #information.”@deepthiw
“My last article couldn't be possible without the platform @deepdyve that makes journal papers cheaper.”@JoseServera